Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Frequency-Dependent Effects of Percutaneous Femoral Nerve Stimulation on Quadriceps Strength (Motor_pPNS)

10 november 2026 uppdaterad av: Xavier Picañol Parraga, Hospital Clinic of Barcelona

Femoral Nerve Stimulation on Knee Extension Strength in Patellar Tendinopathy: A Randomized Crossover Trial

Peripheral nerve stimulation (PNS) is used to manage musculoskeletal pain and may also influence the neural mechanisms involved in voluntary muscle activation. However, whether different stimulation protocols produce distinct effects on muscle strength in individuals with persistent musculoskeletal pain remains unclear.

This randomized, blinded, crossover clinical trial investigates the acute effects of three femoral nerve stimulation protocols on quadriceps muscle function in individuals with persistent patellar tendinopathy. Each participant receives three interventions in a randomized sequence, separated by washout periods of at least 7 days: (1) high-frequency percutaneous peripheral nerve stimulation (HF-pPNS; 100 Hz), (2) low-frequency percutaneous peripheral nerve stimulation (LF-pPNS; 2 Hz), and (3) sensory-level transcutaneous electrical nerve stimulation (s-TENS; 100 Hz). Percutaneous interventions are administered under ultrasound guidance, whereas s-TENS is delivered using surface electrodes.

Quadriceps maximal voluntary contraction (MVC) and rate of force development (RFD) are assessed before stimulation and at 2, 10, 15, and 30 minutes after each intervention. Pain experienced during muscle strength testing, intervention tolerability, and adverse events are also evaluated.

The primary objective is to determine whether these stimulation protocols produce different acute changes in voluntary quadriceps force production. The study also examines interindividual variability in motor responses and explores their associations with pain during voluntary contraction and baseline clinical status.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

19

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Barcelona
      • Barcelona, Barcelona, Spanien, 08020
        • Blanquerna University

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 40 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Manlig

Beskrivning

Inclusion Criteria

  • Adults aged 18-40 years.
  • Individuals with clinically diagnosed patellar tendinopathy lasting ≥3 months.
  • Ultrasound findings consistent with patellar tendinopathy, including tendon thickening, hypoechoic areas, or neovascularization.
  • Pain during tendon-loading activities (e.g., jumping, running, or squatting).
  • Ability to perform maximal voluntary isometric quadriceps contractions and comply with all experimental procedures and sessions.
  • Ability and willingness to provide written informed consent prior to participation.

Exclusion Criteria

  • Knee surgery or traumatic knee injury within the preceding 12 months.
  • Partial or complete patellar tendon rupture.
  • Neurological or neuromuscular disorders affecting lower-limb motor function, including radiculopathy or peripheral neuropathy.
  • Contraindications to electrical stimulation or percutaneous procedures, including implanted electrical devices, skin infections, or open wounds at the stimulation site.
  • Use of analgesics or anti-inflammatory medications, or receipt of corticosteroid injections, within the preceding 48 hours.
  • Participation in another interventional study within the preceding 30 days.
  • Pregnancy or suspected pregnancy.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: High-frequency percutaneous peripheral nerve stimulation (HF-pPNS)

Participants receive HF-pPNS as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.

High-frequency percutaneous peripheral nerve stimulation (HF-pPNS) is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Valencia, Spain), which generates symmetrical biphasic pulses. The femoral nerve is identified at the inguinal level using a SonoScape E1 Exp ultrasound system (SonoScape Medical Corp., Shenzhen, China). Under real-time ultrasound guidance, a sterile acupuncture needle (0.30 × 50 mm) is inserted in-plane and positioned lateral to the femoral nerve, avoiding adjacent vessels. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Stimulation is administered at 100 Hz in five 5-second trains separated by 55-second rest intervals. Intensity is adjusted to the highest pain-free current eliciting visible quadriceps contraction. Participants receive one session, with at least 7 days between crossover conditions.

Andra namn:
  • HF-pPNS
Experimentell: Low-frequency percutaneous peripheral nerve stimulation (LF-pPNS)

Participants receive LF-pPNS as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.

Low-frequency percutaneous peripheral nerve stimulation (LF-pPNS) is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Valencia, Spain), which generates symmetrical biphasic pulses. The femoral nerve is identified at the inguinal level using a SonoScape E1 Exp ultrasound system (SonoScape Medical Corp., Shenzhen, China). Under real-time ultrasound guidance, a sterile acupuncture needle (0.30 × 50 mm) is inserted in-plane and positioned lateral to the femoral nerve, avoiding adjacent vessels. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Stimulation is administered continuously at 2 Hz for 16 minutes. Intensity is adjusted to the highest pain-free current eliciting visible quadriceps contraction. Participants receive one session, with at least 7 days between crossover conditions.

Andra namn:
  • LF-pPNS
Aktiv komparator: Sensory-level transcutaneous femoral nerve stimulation (s-TENS)

Participants receive s-TENS targeting the femoral nerve as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.

Sensory-level transcutaneous electrical nerve stimulation (s-TENS) is administered targeting the femoral nerve at the inguinal level. The femoral nerve is identified under ultrasound guidance (SonoScape E1 Exp, SonoScape Medical Corp., China), and a self-adhesive surface electrode (5 × 5 cm) is positioned over the nerve. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Electrical stimulation is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Spain), generating symmetrical biphasic pulses continuously at 100 Hz for 16 minutes. Intensity is individually adjusted to elicit a clear paresthetic sensation without visible quadriceps contraction. Each participant receives one s-TENS session, with a minimum 7-day washout between crossover conditions.

Andra namn:
  • s-TENS

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Quadriceps Maximal Isometric Voluntary Contraction
Tidsram: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.

Quadriceps maximal voluntary isometric contraction (MVC) is measured on the symptomatic limb using a Chronojump Force Sensor Kit (Chronojump, Barcelona, Spain). Participants are seated with the hip flexed at 90° and the knee positioned at 60°. Following a standardized warm-up and familiarization procedure, participants perform three 4-second maximal voluntary isometric knee-extension contractions, separated by 10-second rest intervals. Real-time visual force feedback is provided, and participants are instructed to contract as fast and as hard as possible from a relaxed state. MVC is defined as the highest peak force recorded across the three trials, expressed in Newtons (N). Absolute and relative changes from baseline are assessed following each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS).

Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Quadriceps Rate of Force Development
Tidsram: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.

Quadriceps rate of force development (RFD) is assessed on the symptomatic limb using a Chronojump Force Sensor Kit (Chronojump, Barcelona, Spain). Participants perform three 4-second maximal voluntary isometric knee-extension contractions, separated by 10-second rest intervals, while instructed to contract as fast and as hard as possible. RFD is calculated from the force-time curve as the slope of force increase during the first 250 milliseconds following contraction onset, expressed in Newtons per second (N/s). Absolute and relative changes from baseline are assessed following each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS).

Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.
Incidence of Adverse Events Assessed Through Post-Intervention Questionnaires
Tidsram: Immediately after each intervention session.

Adverse events potentially associated with peripheral nerve stimulation are assessed using a structured questionnaire completed at the end of each experimental session. Participants report the presence and intensity of sensory symptoms (pain, burning, itching), local skin reactions (erythema, swelling, bruising), and systemic symptoms (fatigue, headache, nausea). Additional unexpected symptoms can also be reported. Symptom intensity is assessed using a numerical rating scale (NRS; 0-10). Adverse events are recorded by type and severity, and their incidence is expressed as the number and percentage of participants reporting each event under each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS). Differences in adverse event frequency and intensity are evaluated across stimulation conditions.

Immediately after each intervention session.
Pain Intensity Evoked by Quadriceps Contraction
Tidsram: Immediately after post-intervention quadriceps strength testing during each experimental session.

Pain intensity experienced during quadriceps maximal voluntary isometric contraction (MVC) is assessed using a 10-cm visual analog scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Participants report the intensity of pain experienced during the strength-testing procedure immediately after its completion. Pain scores are recorded for each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS) to characterize pain experienced during voluntary force production and explore its association with changes in quadriceps strength.

Immediately after post-intervention quadriceps strength testing during each experimental session.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 september 2025

Primärt slutförande (Faktisk)

14 januari 2026

Avslutad studie (Faktisk)

4 november 2026

Studieregistreringsdatum

Först inskickad

15 november 2025

Först inskickad som uppfyllde QC-kriterierna

15 november 2025

Första postat (Faktisk)

20 november 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

De-identified individual participant data underlying the results reported in the published article will be available from the corresponding author upon reasonable request. These data may include maximal voluntary contraction (MVC), rate of force development (RFD), pain ratings, baseline clinical characteristics, stimulation conditions, and adverse events. Data sharing will be subject to applicable ethical approvals, institutional policies, and data protection requirements. Requests will be evaluated based on their scientific rationale and methodological soundness.

Tidsram för IPD-delning

De-identified individual participant data will be available upon reasonable request beginning at the time of publication of the study results and for a period of five years thereafter.

Kriterier för IPD Sharing Access

De-identified individual participant data underlying the published results will be available to qualified researchers upon reasonable request to the corresponding author. Requests must include a scientifically sound research proposal describing the intended use of the data. Access will be subject to approval by the research team and compliance with applicable ethical, institutional, and data protection requirements. A data-sharing agreement may be required before data transfer.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera